London Stocks Climb on Key Data
European stocks ended higher ahead of the U.S. Federal Reserve's interest policy decision Tuesday afternoon. Swiss drug giant Novartis buoyed sentiment with positive comments about its drug for complications related to cancer, Zometa, which received U.S. marketing approval on Monday.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.